1.

Följande poster ska införas: Index nr Kemiskt namn EG-nr CAS-nr Klassificering Märkning Särskilda koncentrationsgränser, M-faktorer och uppskattad akut toxicitet (ATE) Anm.: Faroklass och kategorikod(er) Faroangivelsekod(er) Faropiktogram, signalordskod(er) Faroangivelsekod(er) Kompl. faroangivelsekod(er) ”007-030-00-3 salpetersyra ...% [C ≤ 70 %] 231-714-2 7697-37-2 Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A H272 H331 H314 GHS03 GHS06 GHS05 Dgr H272 H331 H314 EUH071 Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2,65 mg/l (ångor) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % B” ”014-048-00-5 kiselkarbidfibrer (med diameter < 3 μm, längd > 5 μm och profilförhållande ≥ 3:1) 206-991-8 409-21-2 308076-74-6 Carc. 1B H350i GHS08 Dgr H350i” ”014-049-00-0 trimetoxivinylsilan; trimetoxi(vinyl)silan 220-449-8 2768-02-7 Skin Sens. 1B H317 GHS07 Wng H317” ”014-050-00-6 tris(2-metoxietoxi)vinylsilan; 6-(2-metoxetoxi)-6-vinyl-2,5,7,10-tetraoxa-6-silaundekan 213-934-0 1067-53-4 Repr. 1B H360FD GHS08 Dgr H360FD” ”016-098-00-3 dimetyldisulfid 210-871-0 624-92-0 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H225 H331 H301 H336 H370 (övre luftvägar, inhalation) H319 H317 H400 H410 GHS02 GHS06 GHS08 GHS09 Dgr H225 H331 H301 H336 H370 (övre luftvägar, inhalation) H319 H317 H410 inhalation: ATE = 5 mg/l (ångor) oral: ATE = 190 mg/kg bw M = 1 M = 10” ”029-024-00-X granulerad koppar; [partikellängd: 0,9 mm–6,0 mm; partikelbredd: 0,494–0,949 mm] 231-159-6 7440-50-8 Aquatic Chronic 2 H411 GHS09 H411” ”029-025-00-5 bis(N-hydroxi-N-nitrosocyklohexylaminato-O,O’)koppar; bis(N-cyklohexyl-diazenium-dioxi)-koppar [Cu-HDO] 239-703-4 312600-89-8 15627-09-5 Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H228 H302 H373 (lever) H318 H400 H410 GHS02 GHS07 GHS08 GHS05 GHS09 Dgr H228 H302 H373 (lever) H318 H410 oral: ATE = 360 mg/kg bw M = 1 M = 1” ”050-031-00-9 dioktyltenndilaurat; [1] dioktyltenndikokosacyloxi-derivat [2] 222-883-3 [1] 293-901-5 [2] 3648-18-8 [1] 91648-39-4 [2] Repr. 1B STOT RE 1 H360D H372 (immunsystem) GHS08 Dgr H360D H372 (immunsystem)” ”601-092-00-0 dibenso[def,p]krysen; dibenso[a,l]pyren 205-886-4 191-30-0 Carc. 1B Muta. 2 H350 H341 GHS08 Dgr H350 H341 Carc. 1B; H350: C ≥ 0,001 %” ”603-237-00-3 ipkonazol (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-klorbensyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmetyl)cyklopentanol – 125225-28-7 115850-69-6 115937-89-8 Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1 H360D H302 H373 (ögon, hud, lever) H410 GHS08 GHS07 GHS09 Dgr H360D H302 H373 (ögon, hud, lever) H410 oral: ATE = 500 mg/kg bw M = 100” ”603-238-00-9 bis(2-(2-metoxietoxi)etyl)eter; tetraglym; tetraetylenglykoldimetyleter; TEGDME 205-594-7 143-24-8 Repr. 1B H360FD GHS08 Dgr H360FD” ”603-239-00-4 paklobutrazol (ISO); (2RS,3RS)-1-(4-klorfenyl)-4,4-dimetyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol – 76738-62-0 Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d H332 H302 H319 H400 H410 GHS08 GHS07 GHS09 Wng H361d H332 H302 H319 H410 inhalation: ATE = 3,13 mg/l (damm eller dimma) oral: ATE = 490 mg/kg bw M = 10 M = 10” ”603-240-00-X 2,2-bis(brommetyl)propan-1,3-diol 221-967-7 3296-90-0 Carc. 1B Muta. 1B H350 H340 GHS08 Dgr H350 H340” ”603-241-00-5 geraniol; (2E)-3,7-dimetylokta-2,6-dien-1-ol 203-377-1 106-24-1 Skin Sens. 1 H317 GHS07 Wng H317” ”605-041-00-3 2-(4-tert-butylbensyl)propionaldehyd 201-289-8 80-54-6 Repr. 1B H360Fd GHS08 Dgr H360Fd” ”607-738-00-8 MCPA-tioetyl (ISO); S-etyl(4-klor-2-metylfenoxi)etantioat; S-etyl-4-klor-o-tolyloxitioacetat 246-831-4 25319-90-8 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (lever) H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 (lever) H410 oral: ATE = 450 mg/kg bw M = 10 M = 10” ”607-740-00-9 diisooktylftalat 248-523-5 27554-26-3 Repr. 1B H360FD GHS08 Dgr H360FD” ”607-741-00-4 4-{[(6-klorpyridin-3-yl)metyl](2,2-difluoretyl)amino}furan-2(5H)-on; flupyradifuron – 951659-40-8 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (muskel) H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 (muskel) H410 oral: ATE = 500 mg/kg bw M = 10 M = 10” ”607-742-00-X tienkarbazonmetyl (ISO); metyl-4-[(4,5-dihydro-3-metoxi-4-metyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-metyltiofen-3-karboxylat – 317815-83-1 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 000 M = 1 000 ” ”607-743-00-5 L-(+)-mjölksyra; (2S)-2-hydroxipropansyra 201-196-2 79-33-4 Skin Corr. 1C Eye Dam. 1 H314 H318 GHS05 Dgr H314 EUH071” ”607-744-00-0 2-metoxietylakrylat 221-499-3 3121-61-7 Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1 H226 H341 H360FD H331 H302 H314 H318 H317 GHS02 GHS05 GHS06 GHS08 Dgr H226 H341 H360FD H331 H302 H314 H317 EUH071 inhalation: ATE = 2,7 mg/l (ångor) oral: ATE = 404 mg/kg bw” ”607-745-00-6 glyoxylsyra …% 206-058-5 298-12-4 Eye Dam. 1 Skin Sens. 1B H318 H317 GHS05 GHS07 Dgr H318 H317 B” ”607-746-00-1 natrium-N-(hydroximetyl)glycinat; [formaldehyd frisatt från natrium-N-(hydroximetyl)glycinat] 274-357-8 70161-44-3 Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H350 H341 H332 H302 H335 H315 H319 H317 GHS08 GHS07 Dgr H350 H341 H332 H302 H335 H315 H319 H317 inhalation: ATE = 3 mg/l (damm eller dimma) oral: ATE = 1 000 mg/kg bw 8 9” ”611-181-00-6 kalium(oxido-NNO-azoxi)cyklohexan; cyklohexylhydroxidiazen-1-oxid, kaliumsalt; [K-HDO] – 66603-10-9 Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 H228 H301 H373 (lever) H315 H318 H411 GHS02 GHS06 GHS08 GHS05 GHS09 Dgr H228 H301 H373 (lever) H315 H318 H411 oral: ATE = 136 mg/kg bw” ”612-294-00-3 N-etyl-N,N-dimetylhexadekan-1-aminiumetylsulfat; mecetroniumetylsulfat; [MES] 221-106-5 3006-10-8 Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H314 H318 H400 H410 GHS05 GHS09 Dgr H314 H410 EUH071 M = 100 M = 1 000 ” ”613-331-00-6 (2RS)-2-[4-(4-klorfenoxi)-2-(trifluormetyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentriflukonazol – 1417782-03-6 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410 M = 1 M = 1” ”613-332-00-1 oxatiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-tiazol-2-yl}piperidin-1-yl)-2-[5-metyl-3-(trifluormetyl)-1H-pyrazol-1-yl]etanon – 1003318-67-9 Aquatic Chronic 1 H410 GHS09 Wng H410 M = 1” ”613-333-00-7 zinkpyrition; (T-4)-bis[1-(hydroxi-.kappa.O)pyridin-2(1H)-tionato-.kappa.S]zink 236-671-3 13463-41-7 Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H301 H372 H318 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H360D H330 H301 H372 H318 H410 inhalation: ATE = 0,14 mg/l (damm eller dimma) oral: ATE = 221 mg/kg bw M = 1 000 M = 10” ”613-334-00-2 flurokloridon (ISO); 3-klor-4-(klormetyl)-1-[3-(trifluormetyl)fenyl]pyrrolidin-2-on 262-661-3 61213-25-0 Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360FD H302 H317 H400 H410 GHS08 GHS07 GHS09 Dgr H360FD H302 H317 H410 oral: ATE = 500 mg/kg bw M = 100 M = 100” ”613-335-00-8 4,5-diklor-2-oktyl-2H-isotiazol-3-on; [DCOIT] 264-843-8 64359-81-5 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H302 H314 H317 H410 EUH071 inhalation: ATE = 0,16 mg/l (damm eller dimma) oral: ATE = 567 mg/kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100” ”613-336-00-3 2-metyl-1,2-bensotiazol-3-(2H)-on; [MBIT] – 2527-66-4 Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 H312 H301 H314 H318 H317 H400 H411 GHS06 GHS05 GHS09 Dgr H312 H301 H314 H317 H410 EUH071 dermal: ATE = 1 000 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1” ”616-228-00-4 3-(difluormetyl)-1-metyl-N-(3’,4’,5’-trifluorbifenyl-2-yl)pyrazol-4-karboxamid; fluxapyroxad – 907204-31-3 Lact. Aquatic Acute 1 Aquatic Chronic 1 H362 H400 H410 GHS09 Wng H362 H410 M = 1 M = 1” ”616-230-00-5 N-(hydroximetyl)akrylamid; metylolakrylamid; [NMA] 213-103-2 924-42-5 Carc. 1B Muta. 1B STOT RE 1 H350 H340 H372 (perifera nervsystemet) GHS08 Dgr H350 H340 H372 (perifera nervsystemet)” ”616-231-00-0 5-fluor-1,3-dimetyl-N-[2-(4-metylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamid; 2’-[(RS)-1,3-dimetylbutyl]-5-fluor-1,3-dimetylpyrazol-4-karboxanilid; penflufen – 494793-67-8 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 1 M = 1” ”616-232-00-6 iprovalikarb (ISO); isopropyl[(2S)-3-metyl-1-{[1-(4-metylfenyl)etyl]amino}-1-oxobutan-2-yl]karbamat – 140923-17-7 Carc. 2 H351 GHS08 Wng H351” ”616-233-00-1 siltiofam (ISO); N-allyl-4,5-dimetyl-2-(trimetylsilyl)tiofen-3-karboxamid – 175217-20-6 STOT RE 2 Aquatic Chronic 2 H373 H411 GHS08 GHS09 Wng H373 H411” ”650-057-00-6 margosaextrakt [kallpressad olja av frön utan skal av Azadirachta indica extraherad med superkritisk koldioxid] 283-644-7 84696-25-3 Aquatic Chronic 3 H412 H412”